{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:31:02Z","timestamp":1787502662421,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":105,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71424-w","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:30:17Z","timestamp":1775255417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome"],"prefix":"10.1038","volume":"17","author":[{"given":"Xuechun","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-2371","authenticated-orcid":false,"given":"Di","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenna","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-6354","authenticated-orcid":false,"given":"Zhongmin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9525-035X","authenticated-orcid":false,"given":"Zhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"71424_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","volume":"22","author":"M Marassi","year":"2023","unstructured":"Marassi, M. & Fadini, G. P. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc. Diabetol. 22, 195 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"71424_CR2","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","volume":"148","author":"SS Khan","year":"2023","unstructured":"Khan, S. S. et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 148, 1982\u20132004 (2023).","journal-title":"Circulation"},{"key":"71424_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148, 1636\u20131664 (2023).","journal-title":"Circulation"},{"key":"71424_CR4","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1681\/ASN.0000000658","volume":"36","author":"Z Xie","year":"2025","unstructured":"Xie, Z. et al. Global burden of the key components of cardiovascular-kidney-metabolic syndrome. J. Am. Soc. Nephrol. 36, 1572\u20131584 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"71424_CR5","doi-asserted-by":"publisher","unstructured":"Mayne, K. J. et al. Cardiovascular-kidney-metabolic syndrome and mortality in a prospective UK cohort study. Eur. J. Prev. Cardiol. zwaf514 https:\/\/doi.org\/10.1093\/eurjpc\/zwaf514 (2025).","DOI":"10.1093\/eurjpc\/zwaf514"},{"key":"71424_CR6","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606\u20131635 (2023).","journal-title":"Circulation"},{"key":"71424_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41581-024-00812-6","volume":"20","author":"SE Quaggin","year":"2024","unstructured":"Quaggin, S. E. & Magod, B. A united vision for cardiovascular-kidney-metabolic health. Nat. Rev. Nephrol. 20, 273\u2013274 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"71424_CR8","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.cmet.2023.10.015","volume":"35","author":"SE Claudel","year":"2023","unstructured":"Claudel, S. E. & Verma, A. Cardiovascular-kidney-metabolic syndrome: a step toward multidisciplinary and inclusive care. Cell Metab. 35, 2104\u20132106 (2023).","journal-title":"Cell Metab."},{"key":"71424_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","volume":"20","author":"DV O\u2019Hara","year":"2024","unstructured":"O\u2019Hara, D. V. et al. Applications of SGLT2 inhibitors beyond glycaemic control. Nat. Rev. Nephrol. 20, 513\u2013529 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"71424_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2337\/dc19-1410","volume":"43","author":"A Avogaro","year":"2020","unstructured":"Avogaro, A., Fadini, G. P. & Del Prato, S. Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. Diab. Care 43, 501\u2013507 (2020).","journal-title":"Diab. Care"},{"key":"71424_CR11","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00125-024-06257-7","volume":"67","author":"DSH Lin","year":"2024","unstructured":"Lin, D. S. H., Lee, J.-K., Huang, K.-C., Lin, T.-T. & Lo, H.-Y. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease. Diabetologia 67, 2459\u20132470 (2024).","journal-title":"Diabetologia"},{"key":"71424_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda, A. et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc. Res. 120, 443\u2013460 (2024).","journal-title":"Cardiovasc. Res."},{"key":"71424_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie, M. R. & Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761\u2013772 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"71424_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer, M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation 146, 1383\u20131405 (2022).","journal-title":"Circulation"},{"key":"71424_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323\u2013334 (2016).","journal-title":"N. Engl. J. Med."},{"key":"71424_CR16","doi-asserted-by":"crossref","unstructured":"Mahmud, F. H. et al. Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial. Nat. Med. 31, 2317\u20132324 (2025).","DOI":"10.1038\/s41591-025-03723-6"},{"key":"71424_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104215","volume":"83","author":"Y-M Gao","year":"2022","unstructured":"Gao, Y.-M. et al. Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming. EBioMedicine 83, 104215 (2022).","journal-title":"EBioMedicine"},{"key":"71424_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon, V. & Verma, S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu. Rev. Physiol. 83, 503\u2013528 (2021).","journal-title":"Annu. Rev. Physiol."},{"key":"71424_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diab. Endocrinol. 9, 22\u201331 (2021).","journal-title":"Lancet Diab. Endocrinol."},{"key":"71424_CR20","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/ndt\/gfaf051","volume":"40","author":"P Romagnani","year":"2025","unstructured":"Romagnani, P. SGLT2 inhibitors in CKD: are they really effective in all patients? Nephrol. Dial. Transplant. 40, 1838\u20131842 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"71424_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s13346-023-01423-7","volume":"14","author":"RW Hammad","year":"2024","unstructured":"Hammad, R. W., Sanad, R. A.-B., Abdelmalak, N. S. & Latif, R. Cubosomal functionalized block copolymer platform for dual delivery of linagliptin and empagliflozin: recent advances in synergistic strategies for maximizing control of high-risk type II diabetes. Drug Deliv. Transl. Res. 14, 678\u2013695 (2024).","journal-title":"Drug Deliv. Transl. Res."},{"key":"71424_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1681\/ASN.0000000608","volume":"36","author":"A Roointan","year":"2025","unstructured":"Roointan, A., Xu, R., Corrie, S., Hagemeyer, C. E. & Alt, K. Nanotherapeutics in kidney disease: innovations, challenges, and future directions. J. Am. Soc. Nephrol. 36, 500\u2013518 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"71424_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jconrel.2021.04.016","volume":"334","author":"Y Huang","year":"2021","unstructured":"Huang, Y., Wang, J., Jiang, K. & Chung, E. J. Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions. J. Control. Rel. 334, 127\u2013137 (2021).","journal-title":"J. Control. Rel."},{"key":"71424_CR24","doi-asserted-by":"publisher","first-page":"110082","DOI":"10.1016\/j.diabres.2022.110082","volume":"192","author":"W-H Tsai","year":"2022","unstructured":"Tsai, W.-H. et al. Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: a network meta-analysis. Diab. Res. Clin. Pract. 192, 110082 (2022).","journal-title":"Diab. Res. Clin. Pract."},{"key":"71424_CR25","doi-asserted-by":"publisher","first-page":"m4147","DOI":"10.1136\/bmj.m4147","volume":"371","author":"G Musso","year":"2020","unstructured":"Musso, G., Saba, F., Cassader, M. & Gambino, R. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ 371, m4147 (2020).","journal-title":"BMJ"},{"key":"71424_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2337\/dc21-2177","volume":"45","author":"GK Dawwas","year":"2022","unstructured":"Dawwas, G. K., Flory, J. H., Hennessy, S., Leonard, C. E. & Lewis, J. D. Comparative safety of sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis. Diab. Care 45, 919\u2013927 (2022).","journal-title":"Diab. Care"},{"key":"71424_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2337\/dc24-2169","volume":"48","author":"C Ljungberg","year":"2025","unstructured":"Ljungberg, C. et al. Risk of urogenital infections in people with type 2 diabetes initiating SGLT2is versus GLP-1RAs in routine clinical care: a Danish cohort study. Diab. Care 48, 945\u2013954 (2025).","journal-title":"Diab. Care"},{"key":"71424_CR28","doi-asserted-by":"publisher","first-page":"102979","DOI":"10.1016\/j.redox.2023.102979","volume":"69","author":"X Li","year":"2024","unstructured":"Li, X. et al. Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE\/PKC\/NOX axis. Redox Biol. 69, 102979 (2024).","journal-title":"Redox Biol."},{"key":"71424_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-024-02298-9","volume":"23","author":"BJ Kasperova","year":"2024","unstructured":"Kasperova, B. J. et al. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure. Cardiovasc. Diabetol. 23, 223 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"71424_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10020-025-01138-0","volume":"31","author":"T Matsui","year":"2025","unstructured":"Matsui, T., Sotokawauchi, A., Nishino, Y., Koga, Y. & Yamagishi, S.-I. Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product-receptor axis. Mol. Med. 31, 88 (2025).","journal-title":"Mol. Med."},{"key":"71424_CR31","first-page":"1201","volume":"14","author":"M Elbadr","year":"2024","unstructured":"Elbadr, M. et al. Protective and therapeutic effects of empagliflozin in nephrotoxicity induced by 5-Fluorouracil in rats: Role of caspase-3, inflammation and oxidative stress. J. Adv. Vet. Res. 14, 1201\u20131207 (2024).","journal-title":"J. Adv. Vet. Res."},{"key":"71424_CR32","doi-asserted-by":"publisher","first-page":"112406","DOI":"10.1016\/j.fct.2021.112406","volume":"155","author":"AT Osman","year":"2021","unstructured":"Osman, A. T., Sharkawi, S. M. Z., Hassan, M. I. A., Abo-Youssef, A. M. & Hemeida, R. A. M. Empagliflozin and neohesperidin protect against methotrexate-induced renal toxicity via suppression of oxidative stress and inflammation in male rats. Food Chem. Toxicol. 155, 112406 (2021).","journal-title":"Food Chem. Toxicol."},{"key":"71424_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1039\/D1CS00686J","volume":"51","author":"M Machtakova","year":"2022","unstructured":"Machtakova, M., Th\u00e9rien-Aubin, H. & Landfester, K. Polymer nano-systems for the encapsulation and delivery of active biomacromolecular therapeutic agents. Chem. Soc. Rev. 51, 128\u2013152 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"71424_CR34","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach, M. A. et al. Polymeric nanoparticles for drug delivery. Chem. Rev. 124, 5505\u20135616 (2024).","journal-title":"Chem. Rev."},{"key":"71424_CR35","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ndt\/gfac233","volume":"38","author":"G Sabiu","year":"2023","unstructured":"Sabiu, G. et al. Targeted nanotherapy for kidney diseases: a comprehensive review. Nephrol. Dial. Transplant. 38, 1385\u20131396 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"71424_CR36","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41581-024-00819-z","volume":"20","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. Physiological principles underlying the kidney targeting of renal nanomedicines. Nat. Rev. Nephrol. 20, 354\u2013370 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"71424_CR37","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrneph.2016.156","volume":"12","author":"N Kamaly","year":"2016","unstructured":"Kamaly, N., He, J. C., Ausiello, D. A. & Farokhzad, O. C. Nanomedicines for renal disease: current status and future applications. Nat. Rev. Nephrol. 12, 738\u2013753 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"71424_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/j.2040-4603.2011.tb00342.x","volume":"1","author":"JD Klein","year":"2011","unstructured":"Klein, J. D., Blount, M. A. & Sands, J. M. Urea transport in the kidney. Compr. Physiol. 1, 699\u2013729 (2011).","journal-title":"Compr. Physiol."},{"key":"71424_CR39","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1681\/ASN.2006101108","volume":"18","author":"RA Fenton","year":"2007","unstructured":"Fenton, R. A. & Knepper, M. A. Urea and renal function in the 21st century: insights from knockout mice. J. Am. Soc. Nephrol. 18, 679\u2013688 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"71424_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54305-y","volume":"15","author":"S-M Huang","year":"2024","unstructured":"Huang, S.-M. et al. Structural insights into the mechanisms of urea permeation and distinct inhibition modes of urea transporters. Nat. Commun. 15, 10226 (2024).","journal-title":"Nat. Commun."},{"key":"71424_CR41","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","volume":"63","author":"R Vanholder","year":"2003","unstructured":"Vanholder, R. et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63, 1934\u20131943 (2003).","journal-title":"Kidney Int."},{"key":"71424_CR42","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1681\/ASN.2011121175","volume":"23","author":"F Duranton","year":"2012","unstructured":"Duranton, F. et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 23, 1258\u20131270 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"71424_CR43","doi-asserted-by":"publisher","first-page":"2419295","DOI":"10.1002\/adfm.202419295","volume":"35","author":"X Ren","year":"2025","unstructured":"Ren, X. et al. UCST polymeric H2S-donor fabricated nanomedicine managing atherosclerosis by gas-photothermal therapy involving a \u201cturning waste into treasure\u201d strategy. Adv. Funct. Mater. 35, 2419295 (2025).","journal-title":"Adv. Funct. Mater."},{"key":"71424_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122883","volume":"314","author":"Z Yang","year":"2025","unstructured":"Yang, Z. et al. Mitochondrial-uncoupling nanomedicine for self-heating and immunometabolism regulation in cancer cells. Biomaterials 314, 122883 (2025).","journal-title":"Biomaterials"},{"key":"71424_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10173","volume":"5","author":"Y Huang","year":"2020","unstructured":"Huang, Y., Jiang, K., Zhang, X. & Chung, E. J. The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles. Bioeng. Transl. Med. 5, e10173 (2020).","journal-title":"Bioeng. Transl. Med."},{"key":"71424_CR46","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1021\/acs.bioconjchem.6b00397","volume":"27","author":"M Janzer","year":"2016","unstructured":"Janzer, M. et al. Drug conjugation affects pharmacokinetics and specificity of kidney-targeted peptide carriers. Bioconjugate Chem. 27, 2441\u20132449 (2016).","journal-title":"Bioconjugate Chem."},{"key":"71424_CR47","first-page":"206","volume":"37","author":"S Shang","year":"2024","unstructured":"Shang, S. et al. Targeted therapy of kidney disease with nanoparticle drug delivery materials. Bioact. Mater. 37, 206\u2013221 (2024).","journal-title":"Bioact. Mater."},{"key":"71424_CR48","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","volume":"8","author":"JW Ostrominski","year":"2023","unstructured":"Ostrominski, J. W. et al. Prevalence and overlap of cardiac, renal, and metabolic conditions in US Adults, 1999-2020. JAMA Cardiol. 8, 1050\u20131060 (2023).","journal-title":"JAMA Cardiol."},{"key":"71424_CR49","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024139","volume":"11","author":"PA McCullough","year":"2022","unstructured":"McCullough, P. A., Amin, A., Pantalone, K. M. & Ronco, C. Cardiorenal nexus: a review with focus on combined chronic heart and kidney failure, and insights from recent clinical trials. J. Am. Heart Assoc. 11, e024139 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"71424_CR50","doi-asserted-by":"crossref","unstructured":"Hatamizadeh, P. et al. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat. Rev. Nephrol. 9, 99\u2013111 (2013).","DOI":"10.1038\/nrneph.2012.279"},{"key":"71424_CR51","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4093\/dmj.2023.0067","volume":"47","author":"SH Suh","year":"2023","unstructured":"Suh, S. H. & Kim, S. W. Dyslipidemia in patients with chronic kidney disease: an updated overview. Diab. Metab. J. 47, 612\u2013629 (2023).","journal-title":"Diab. Metab. J."},{"key":"71424_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","volume":"14","author":"CJ Ferro","year":"2018","unstructured":"Ferro, C. J. et al. Lipid management in patients with chronic kidney disease. Nat. Rev. Nephrol. 14, 727\u2013749 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"71424_CR53","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMc1600827","volume":"374","author":"PA Sarafidis","year":"2016","unstructured":"Sarafidis, P. A. & Tsapas, A. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 374, 1092 (2016).","journal-title":"N. Engl. J. Med."},{"key":"71424_CR54","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay, M. S. et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diab. Care 41, 1801\u20131808 (2018).","journal-title":"Diab. Care"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71424-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:02:55Z","timestamp":1784286175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71424-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71424"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71424-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6426"}}